Intelligence · Clinical Development
Pipeline search results
Programs matching “monoclonal” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 32 pipeline programs matching "monoclonal" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
KT-US-679-0788
Lacuna Pharma Pty Ltd
Relapsed/refractory multiple myeloma in patients who have received 1 to 3 prior lines of therapy and have been exposed to both an immunomodulatory drug and an anti-CD38 monoclonal antibody
1 trial -
Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 200 mg
Sunshine Guojian Pharmaceutical (Shanghai) Co.,
Acute Gout
2 trials -
ziltivekimab, Ziltivekimab
NovoThirteen
The medical condition we are investigating is type 1 AMI (STEMI and NSTEMI). Ziltivekimab is a human monoclonal antibody directed against the interleukin-6 (IL-6) ligand, and currently available clinical data support that ziltivekimab once-monthly reduces inflammation as measured by highsensitivity C-reactive protein (hs-CRP). With the recent proof-of-concept that hs-CRP reduction through inhibition of an upstream pathway leads to reduction in cardiovascular events, it is reasonable to expect that similar inhibition of IL-6 with ziltivekimab also reduces CV risk.The aim of the current study is to demonstrate the efficacy and safety of ziltivekimab in reducing the risk of major adverse cardiovascular events when initiated as early as possible in adult patients with ST-elevation and non-ST-elevation myocardial infarction
1 trial -
Anti-CD40 Agonist Monoclonal Antibody CDX-1140
United Therapeutics Europe Ltd
Ovarian Clear Cell Adenocarcinoma
1 trial -
Anti-human CCL24 monoclonal antibody (CM-101)
Chemomab Therapeutics
Primary Sclerosing Cholangitis
1 trial -
CRB-601 monoclonal antibody
Corbus Pharmaceuticals Holdings
Solid Tumor
1 trial -
Humanized anti-CD117 Monoclonal Antibody (JSP191)
Jasper Therapeutics
SCID
1 trial -
IBRUTINIB
Fondazione Telethon ETS
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or CLL-like monoclonal B-cell lymphocytosis
1 trial -
Linvoseltamab
Regeneron UK Limited
Monoclonal Gammopathy of Undetermined Significance (MGUS)
1 trial -
PD -1/PD-L1 monoclonal antibody plus radiotherapy and liver transplantation
The First People's Hospital of Lianyungang
Locally Advanced Perihilar Cholangiocarcinoma
1 trial -
R5458-ONC-2257
Lacuna Pharma Pty Ltd
High-Risk Monoclonal Gammopathy of Undetermined Significance; Non-High-Risk Smoldering Multiple Myeloma
1 trial -
Recombinant Anti-IL-17A Humanized Monoclonal Antibody Injection
Sunshine Guojian Pharmaceutical (Shanghai) Co.,
Psoriasis
1 trial -
Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 100 mg
Sunshine Guojian Pharmaceutical (Shanghai) Co.,
Gout Arthritis
1 trial -
Recombinant anti-PD-1 humanized monoclonal antibody injection
Sunshine Guojian Pharmaceutical (Shanghai) Co.,
Sarcoma, Soft Tissue
1 trial -
Rituximab combined with Daratumumab（Anti-CD38 Monoclonal Antibody）
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Immune Thrombocytopenia
1 trial -
TNFα Monoclonal Antibody
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Spinal Cord Injuries
1 trial -
monoclonal factor IX replacement therapy
Ultragenyx UK Limited
Hemophilia B
1 trial -
recombinant humanized anti-CD25 monoclonal antibody
The First People's Hospital of Lianyungang
Transfusion Dependent Thalassemia
1 trial -
124I-labeled monoclonal antibody Mu 11-1F4
BRIGHT MINDS BIOSCIENCES INC.
AL Amyloidosis
1 trial -
ACTINIUM-225-LABELED HUMANIZED ANTI-CD33 MONOCLONAL ANTIBODY HuM195
Actinium Pharmaceuticals
Leukemia
1 trial -
Anti-CD20 monoclonal antibody and the BTK inhibitor
The First People's Hospital of Lianyungang
Anti-CD20 Monoclonal Antibody
1 trial -
Anti-SEMA4D Monoclonal Antibody VX15/2503
VACCINEX, INC.
Metastatic Melanoma
1 trial -
Anti-SEMA4D Monoclonal Antibody VX15/2503
VACCINEX, INC.
Colon Carcinoma Metastatic in the Liver
1 trial -
Anti-human CCL24 monoclonal antibody (CM-101)
Chemomab Therapeutics
Healthy
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.